Dyne Therapeutics CFO Sparks Investor Optimism with Massive Zero‑Cost Stock Purchase Wave.
Dyne Therapeutics CFO Lucera Erick buys 65,000 shares and 105,000 options at zero cost – a bullish insider signal that could precede a stock rebound if clinical milestones materialize.
3 minutes to read